Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.
about
From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implicationsOxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological rolePCSK9 inhibition in the management of hyperlipidemia: focus on evolocumabLDL cholesterol, statins and PCSK 9 inhibitorsCurrent therapies for lowering lipoprotein (a)Profile of evolocumab and its potential in the treatment of hyperlipidemiaThe year in cardiology 2015: preventionPCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic eraPCSK9 inhibitors - mechanisms of actionHuman Genetics and the Causal Role of Lipoprotein(a) for Various DiseasesLow-normal thyroid function and novel cardiometabolic biomarkersLipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptorGuidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data.PCSK9 and Atherosclerosis - Lipids and Beyond.Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysisPCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a reviewPCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).PCSK9 antibodies for the treatment of hypercholesterolemiaPCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9.Acute and chronic impact of cardiovascular events on health state utilities.High prevalence of raised lipoprotein(a) in patients with refractory anginaComparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials.Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humansPopulation and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study.The Treatment of Disorders of Lipid MetabolismPCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis.Recurrent Embolic Strokes of Undetermined Source in a Patient with Extreme Lipoprotein(a) LevelsCorrelation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery diseaseLipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease riskEfficacy and safety of different doses of evolocumab in reducing low-density lipoprotein cholesterol levels: A meta-analysisProprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy.PCSK9 inhibition: current concepts and lessons from human genetics.Targeting PCSK9 for therapeutic gainsTargeting lipoprotein (a): an evolving therapeutic landscape.Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.Update of Clinical Trials of Anti-PCSK9 Antibodies.
P2860
Q26741078-8ABFD3FC-9BC4-4D7C-8230-633EEB63FD36Q26747100-4BF26EBA-AB63-4A1F-937C-122178E14A2AQ26747776-2562432B-4691-49B2-A6D7-44A540D32977Q26782522-D06AD00C-0FC6-4E57-993B-74441B679350Q26830297-0076CF43-F682-4C00-985B-6BA4936D9869Q27004235-5C926B63-05D3-4CB7-B223-4B38ACF7ED4CQ28072221-568ABC95-5243-4814-B1CF-2FD6C0A43D7AQ28073656-154D951B-C961-4B17-AFD2-3091FC66C85DQ28073987-463BB4D1-A43B-406C-AD3A-92B009F84D5BQ28079294-78175367-D4AF-4CA5-9E3B-959131C2AB97Q28084990-019FAC17-FCBD-45DC-9101-1D2AA589B256Q28258969-F2175A1F-E062-4AA1-9B4A-E28047AA6CC3Q30276550-B0049BA6-4737-4E5F-8AF1-88D665039AE9Q30833167-CDAB90FC-5793-4168-B062-54E4E5A665FFQ33675963-3ADF5BD4-9D37-450C-A878-B4ABE501E3E7Q33831563-99ABD707-5860-47F1-9585-53E53F6C2787Q33904455-760336B7-020B-4522-BFA9-ADE3BB4ACF11Q34238630-414F8806-F137-4DEE-9875-C74CD73531CFQ34433146-7E2AC132-9D62-43AF-8139-5E964E4DE6D0Q34458693-CDEA70FF-EDA6-4FDD-BA38-31EABD2F1133Q34774969-11268FDD-DE14-4458-BAF3-06F3A61C5E49Q35262593-558961ED-013C-43FF-A99F-36C51366448BQ35534337-8B391E0F-C008-48AC-974D-B7484835C39DQ36187468-70358473-F979-4422-BF88-385109B44F25Q36268257-4435C35D-D6CD-4EA0-8800-29398C202477Q36617508-4612308A-C1F6-4FC9-B130-151DFA0D3F69Q36731797-98BF91DA-7DA3-4737-BA8C-F426E0AAC939Q36882866-5DC86AFE-A5E2-4F07-AF5B-E60964713C23Q36930207-451AB095-8A60-4294-A348-32BF610F265DQ36930213-CE4A0E9F-4774-4C8E-8580-55155865F95EQ37218193-EDCD8B8D-534E-4E36-B091-9968DFC80E4DQ37278608-48C729F5-4E8C-47C1-93AA-AEA843928A6AQ37334501-B2DEA917-2F99-45EC-9F1C-FADE86AB4E16Q37406241-6F2D860A-D541-4852-A501-6F76A621C2D8Q38285812-5A839E65-11AC-4528-9568-0F4C408A1511Q38338236-A347F47C-B44B-4E76-A89A-1D98BF886EB2Q38364882-F553645E-E976-4D4E-91F4-5CA4651ECDE2Q38367355-FA7BFF3D-FA8D-4F14-A200-F93848C84BE6Q38424373-17289E9A-4B72-49ED-9AA3-8F739EB4CFCEQ38444379-2B70037A-9152-4C5A-8E72-16D351E8C6F2
P2860
Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Reduction in lipoprotein(a) wi ...... patients in 4 phase II trials.
@en
Reduction in lipoprotein(a) wi ...... patients in 4 phase II trials.
@nl
type
label
Reduction in lipoprotein(a) wi ...... patients in 4 phase II trials.
@en
Reduction in lipoprotein(a) wi ...... patients in 4 phase II trials.
@nl
prefLabel
Reduction in lipoprotein(a) wi ...... patients in 4 phase II trials.
@en
Reduction in lipoprotein(a) wi ...... patients in 4 phase II trials.
@nl
P2093
P50
P921
P1476
Reduction in lipoprotein(a) wi ...... patients in 4 phase II trials
@en
P2093
Evan A Stein
Fannie Huang
Frederick J Raal
Gisle Langslet
Harold Bays
Marc S Sabatine
Michael J Koren
Moetaz Albizem
Ricardo Dent
P304
P356
10.1016/J.JACC.2014.01.006
P407
P577
2014-02-05T00:00:00Z